Immune-Onc Therapeutics

Return to Grants

Total Awards:
Award Value:
Institution type:
For profit
Short Name:
Immune-Onc Therapeutics

Awards to the Institution

Program Type Investigator Grant Title Award Value
Clinical Trial Stage Projects Joseph Paul Woodard Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML $6,000,000